Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/ovid-halts-preclinical-work-iv-seizure-program-wake-soticlestats-phase-3-stumble
https://www.globenewswire.com/news-release/2024/07/30/2920935/0/en/Ovid-Therapeutics-to-Present-at-Upcoming-August-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/07/23/2917144/0/en/Ovid-Therapeutics-Expands-Scientific-Advisory-Board-with-Appointments-of-Leading-Neurologists-Neuroscientists-and-Epileptologists.html
https://www.globenewswire.com/news-release/2024/07/10/2911069/0/en/eNeuro-Publishes-Findings-on-the-Anti-Convulsant-Properties-of-OV329-and-Its-Potential-Effectiveness-in-Treatment-Resistant-Seizures.html
https://www.globenewswire.com/news-release/2024/07/01/2906636/0/en/Ovid-Therapeutics-and-Graviton-Bioscience-Announce-Topline-Data-from-a-Phase-1-Clinical-Trial-Studying-OV888-GV101-Capsule-a-Potential-First-In-Class-Therapy-for-Cerebral-Cavernous.html
https://www.reuters.com/business/healthcare-pharmaceuticals/takedas-seizure-drug-fails-meet-main-goal-late-stage-studies-2024-06-17/
https://www.globenewswire.com/news-release/2024/06/17/2899490/0/en/Ovid-Therapeutics-Reports-on-Takeda-s-Announcement-of-Phase-3-Topline-Study-Results-for-Soticlestat.html
https://www.globenewswire.com/news-release/2024/05/14/2881336/0/en/Ovid-Therapeutics-Reports-Business-Updates-and-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/13/2880273/0/en/Ovid-Therapeutics-to-Present-at-the-H-C-Wainwright-2nd-Annual-BioConnect-Investor-Conference.html
https://www.globenewswire.com/news-release/2024/04/04/2857730/0/en/Ovid-Therapeutics-to-Present-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html